Showing results (81-90 of 93) with videos related to

Sort By:
Pageof 10
Journal of the American College of Cardiology|June 27, 2009
Updated clinical classification of pulmonary hypertensionGérald Simonneau, Ivan M Robbins, Maurice Beghetti, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|June 9, 2024
Application of REVEAL Lite 2 and COMPERA 2.0 risk scores to patients with pulmonary arterial hypertension switching to riociguat in the REPLACE studyRaymond L Benza, Gérald Simonneau, Hossein-Ardeschir Ghofrani, et al.
The European Respiratory Journal|September 11, 2017
RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitorsMarius M Hoeper, Gérald Simonneau, Paul A Corris, et al.
Pulmonary Circulation|January 26, 2026
Knowledge Gaps and Controversies on Cardiopulmonary Exercise Testing in the Assessment of Pulmonary Vascular Disease: An Official Statement of the Pulmonary Vascular Research Institute Exercise and Right Ventricular Function Task ForceAaron B Waxman, Abraham Babu, Roberto Badagliacca, et al.
The Lancet. Respiratory Medicine|September 22, 2024
Safety and efficacy of rodatristat ethyl for the treatment of pulmonary arterial hypertension (ELEVATE-2): a dose-ranging, randomised, multicentre, phase 2b trialOlivier Sitbon, Andris Skride, Jeremy Feldman, et al.
Pulmonary Circulation|December 8, 2025
Transitioning From Parenteral Prostanoids to Oral Selexipag in Pulmonary Arterial Hypertension: A Multicenter Retrospective Cohort StudyBrandon Budhram, Sarah K Alrasheed, Moaaz Rashad, et al.
Chest|November 19, 2019
Results of an Expert Consensus Survey on the Treatment of Pulmonary Arterial Hypertension With Oral Prostacyclin Pathway AgentsVallerie V McLaughlin, Richard Channick, Teresa De Marco, et al.
American Heart Journal|June 1, 2002
Effects of the thromboxane synthetase inhibitor and receptor antagonist terbogrel in patients with primary pulmonary hypertensionDavid Langleben, Brian W Christman, Robyn J Barst, et al.
American Heart Journal|August 23, 2006
Temporal trends and drug exposures in pulmonary hypertension: an American experienceAlexander M Walker, David Langleben, James J Korelitz, et al.
American Journal of Respiratory and Critical Care Medicine|February 25, 2026
Phase 2b trial of inhaled imatinib for treatment of pulmonary arterial hypertensionNicholas S Hill, Hunter Gillies, Murali M Chakinala, et al.
Pageof 10